ARRIVENT BIOPHARMA INC(NASDAQ:AVBP) stock Fundamental Analysis

Fundamental Rating

AVBP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for AVBP as it has an excellent financial health rating, but there are worries on the profitability. AVBP does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year AVBP has reported negative net income.

In the past year AVBP has reported a negative cash flow from operations.

1.2 Ratios

The Return On Assets of AVBP (-29.27%) is better than 67.55% of its industry peers.

The Return On Equity of AVBP (-31.24%) is better than 77.25% of its industry peers.

		Industry Rank	Sector Rank
ROA	-29.27%
ROE	-31.24%
ROIC	N/A

ROA(3y)-30.66%

ROA(5y)N/A

ROE(3y)-32.74%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

AVBP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

AVBP has more shares outstanding than it did 1 year ago.

There is no outstanding debt for AVBP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 23.15 indicates that AVBP is not in any danger for bankruptcy at the moment.

AVBP has a better Altman-Z score (23.15) than 95.24% of its industry peers.

AVBP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	23.15

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

AVBP has a Current Ratio of 13.14. This indicates that AVBP is financially healthy and has no problem in meeting its short term obligations.

AVBP's Current ratio of 13.14 is amongst the best of the industry. AVBP outperforms 86.77% of its industry peers.

AVBP has a Quick Ratio of 13.14. This indicates that AVBP is financially healthy and has no problem in meeting its short term obligations.

AVBP's Quick ratio of 13.14 is amongst the best of the industry. AVBP outperforms 86.77% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	13.14
Quick Ratio	13.14

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

AVBP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.89%.

EPS 1Y (TTM)-17.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%7.72%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

AVBP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.68% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-16.08%

EPS Next 2Y-18.26%

EPS Next 3Y6.1%

EPS Next 5Y27.68%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AVBP. In the last year negative earnings were reported.

Also next year AVBP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-18.26%

EPS Next 3Y6.1%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for AVBP!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ARRIVENT BIOPHARMA INC

NASDAQ:AVBP (4/25/2025, 8:00:00 PM)

After market: 20.82 0 (0%)

20.82

-0.35 (-1.65%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)03-03 2025-03-03/bmo

Earnings (Next)05-07 2025-05-07

Inst Owners70.84%

Inst Owner Change-72.63%

Ins Owners15.2%

Ins Owner Change0%

Market Cap708.30M

Analysts87.69

Price Target40.07 (92.46%)

Short Float %17.09%

Short Ratio18.86

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)31.64%

Min EPS beat(2)23.03%

Max EPS beat(2)40.25%

EPS beat(4)4

Avg EPS beat(4)25.42%

Min EPS beat(4)0.94%

Max EPS beat(4)40.25%

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)1.78%

PT rev (3m)3.38%

EPS NQ rev (1m)0%

EPS NQ rev (3m)16.3%

EPS NY rev (1m)0%

EPS NY rev (3m)11.09%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.75
P/tB	2.75
EV/EBITDA	N/A

EPS(TTM)-2.57

EYN/A

EPS(NY)-2.98

Fwd EYN/A

FCF(TTM)-2.06

FCFYN/A

OCF(TTM)-2.06

OCFYN/A

SpS0

BVpS7.57

TBVpS7.57

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-29.27%
ROE	-31.24%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-30.66%

ROA(5y)N/A

ROE(3y)-32.74%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	13.14
Quick Ratio	13.14
Altman-Z	23.15

F-Score5

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-17.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%7.72%

EPS Next Y-16.08%

EPS Next 2Y-18.26%

EPS Next 3Y6.1%

EPS Next 5Y27.68%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-26.44%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year22.21%

EBIT Next 3Y17.03%

EBIT Next 5YN/A

FCF growth 1Y-25.73%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-25.73%

OCF growth 3YN/A

OCF growth 5YN/A

ARRIVENT BIOPHARMA INC (AVBP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens